BBBassim Al Bahrani

Bassim Al Bahrani

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Bassim Al Bahrani has a total of 84 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Cancer Incidence in Oman (1996–2015)

    by Jawad A. Al-Lawati, Ibrahim Al-Zakwani, Ibtihal Fadhil, Bassim J. Al-Bahrani


  • Open Access

    Long-term survival in a case of metastatic papillary renal cell carcinoma

    by Abdul Monem Essam, Ajit Venniyoor, Suresh Nagdev, Itrat Mehdi, Bassim Al Bahrani

    Publication Date: 22 December 2020 (online) © 2017. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. https://creativecommons.org/licenses/by-nc-nd/4.0/. Thieme Medical and Scientific Publishers Pvt. Ltd. A-12, 2nd Floor, Sector 2, Noida-201301 UP, India


  • Open Access

    Minocycline Improves the Efficacy of EGFR Inhibitor Therapy: A Hypothesis

    by Ajit Venniyoor, Bassim Al Bahrani

    Skin rash is a side effect of drugs that inhibit Epithelial Growth Factor Receptor (EGFR) as a part of targeted therapy of cancer. It’s appearance and severity correlates with survival. Minocycline, an oral tetracycline antibiotic, is recommended as treatment (and increasingly, for prevention) of the rash, though infection is seen in only one-third of the patients. Minocycline has additional anti-cancer properties such as poly (ADP-ribose) polymerase (PARP) inhibition. It is proposed that such properties contribute to the efficacy of EGFR-inhibitors, and can also explain the positive correlation between grade of rash and survival as patients with higher grades of rash are more likely to receive minocycline. Early concurrent administration of minocycline is recommended in patients planned for EGFR therapy while awaiting trials proving this hypothesis.


  • Open Access

    Primary Gastric Chorioadenocarcinoma

    by Bahaaeldin A. Baraka, Suad S. Al Kharusi, Bassim J. Al Bahrani, Gunmala Bhathagar

    Primary gastric chorioadenocarcinoma (PGC) is a rare and rapidly invasive tumor. Choriocarcinoma is usually known to be of endometrial origin and gestational; however, it has been reported in other extragenital organs, such as the gall bladder, prostate, lung, liver, and the gastrointestinal tract. Human chorionic gonadotropin related neoplasms of the stomach are seldom discussed in the literature. We report a case of PGC in a 56-year-old man treated with a standard non-gestational choriocarcinoma chemotherapy regimen, EMA/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine), with a complete response and good tolerability.


    • 1 January 2016
      • Vol. 17  (6) , 2801-4

    High Occurrence of Non-Clear Cell Renal Cell Carcinoma in Oman.

    by Ajit Venniyoor, Abdul Monem Essam, Fatma Ramadhan, Heeranand Keswani, Itrat Mehdi, Bassim Al Bahrani

    It is conventionally accepted that renal cell carcinoma (RCC) occurs in older patients and the clear cell type is the most common histology. However, ethnic variations exist and this study was carried out to determine the epidemiological pattern of RCC in Oman. Ninety RCC patients who presented to a tertiary care center in the Sultanate of Oman from 2010 to 2014 were studied. The main findings were that the median age of presentation was low, more patients presented with localized stage, and there was a higher incidence of non-clear (especially papillary) histology. Data from other Gulf countries and possible reasons for the different profile are discussed.

    • 1 August 2014
      • Vol. 64  (8) , 863-8

    Utilization of systemic palliative chemotherapy at the end of life: a local experience.

    by Essam Abdul Monem, Itrat Mehdi, Bassim Jaffa Al Bahrani, Ayman Mohammad Nada, Suad Al Kharusi

    To evaluate attitude towards using systemic chemotherapy near the end of life for cancer patients. This retrospective study comprised data of all patients who died with cancer at the Medical Oncology Department of the National Oncology Centre, Muscat, Oman, from January 2009 to December 2011. The records were retrieved from the electronic patient record system of ALSHIFA, Royal Hospital. Demographic data, chemotherapy at end of life, performance status, 'do not resuscitate' status, hospitalisation, and chemotherapy toxicity were analysed. The mean age of the 261 patients in the study was 52.3 +/- 14.52 years. Ninety-two (35%) patients did not receive chemotherapy in the last 3 months of their lives. Chemotherapy administered at end of life was 169 (65%), 126 (48%), and 75 (29%) in last 3 months, one month and 2 weeks of life. Those who received more than 3 lines of chemotherapy were 66 (36%). The end-of-life use of chemotherapy should always be carefully discussed. The patient's right to information should be honoured. The transition from active to best supportive care should be carefully guided.


  • Open Access

    Age at diagnosis of female breast cancer in Oman: Issues and implications

    by Itrat Mehdi, Essam Abdul Monem, Bassim Jaffar Al Bahrani, Suad Al Kharusi, Ayman Mohammad Nada, Jawad Al Lawati, Najla Al Lawati

    Introduction: Female breast cancer (BC) is the most frequent malignancy diagnosed globally, about 23% of the diagnosed cancers. BC incidence varies geographically, highest in Western Europe and lowest in Africa. BC in females is strongly correlated to age, the highest incidence rate amongst older women reinforcing the importance of hormonal status. BC in young females has an aggressive phenotype. There is a shared observation amongst practicing oncologists that BC in Middle East and the developing world presents at an earlier age. Aim and Objective: The aims of this study are to evaluate the age at presentation of female BC in Oman, and to compare our data with international and regional published data. It discusses the impact of young age Breast Cancer. Materials and Methods: All diagnosed female BC cases registered from 1996-2010 all over the country, were retrieved from the National Cancer Registry, Ministry of Health. BC cases were analyzed with respect to age at presentation. The data were compared with regional and international data. Results: A total of 14,109 cancer cases were recorded during the period of study. BC was the leading malignancy as 1,294 cases (9.1%). Female BC patients were 1,230; denoting 19.2% of all female cancers. 53.5% of female BC presented below 50 years of age. Male BC constituted 5% of total, with 67% of male BC occurring over 50 years of age. Compared with data from Oman, the highest rates in UK and other Western countries are above 50 years of age. These rates are four to 10 times higher than local in different age groups. Interestingly, these rates increase with increasing age in UK from 40-45 to up to 85+, keep on increasing and go up to four times higher with higher age. This phenomenon, of increasing incidence rates with age, is not observed in our local population. Discussion: BC is significantly correlated to age as reported from Western population. BC is reported at a younger age from developing and Arab World, which need to be further studied and validated. This phenomenon of BC in younger age may have significant implications and effects ranging from screening, diagnosis, management, prognosis, and cost of treatment. Conclusion: The impact on young women diagnosed with BC is enormous, ranging from psychosocial to healthcare services and economics. There is a need to study it further in depth in developing World.


    • 1 January 2014
      • Vol. 1  (15) , 38-48

    Breast cancer molecular subtypes in oman: correlation with age, histology, and stage distribution - analysis of 542 cases.

    by I Mehdi, A A Monem, Bassim Al Bahrani, F A Ramadhan

    Breast cancer (BC) is one of the most common malignancies and a foremost health issue throughout world. BC accounted for 23.1% of cancer cases diagnosed in Oman in 2009. BC is a heterogeneous disease, and immuno-histochemical (IHC) markers are used to further classify it into distinct subtypes, which are biologically discrete and display different behaviors. IHC testing of the estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor-2 (Her-2); can sub-classify BC into 4 principal molecular subtypes. These subtypes are luminal A (ER+ and/or PR+, HER2-), luminal B (ER+ and/or PR+, HER2+), basal like (BCL - ER-, PR-, HER2-), and Her2/neu (ER-, PR-, HER2+). Previous studies have shown preliminary evidence and high probabilities of molecular differences across ethnic and geographic groups which may be responsible for disparities in presentation, biological behavior, treatment response and outcome. BC data from 2006-2010 at the National Oncology Center - The Royal Hospital, Oman were retrospectively retrieved from the electronic patient record system (Al-Shifa). Data were analyzed with respect to ER, PR, and Her-2 status and tumours were classified on molecular basis. Molecular subtypes were correlated with age, histology and treatment outcome. The results were compared with published regional and international data. There were 542 cases of BC accessible for evaluation. Luminal A subtype was the most common and the BCL subtype was highest among Omani females. Age was a significant factor in basal-like (63.8% younger than 50 years vs. 36.2% older than 50 years) and Her2 +ve tumours (60.9% vs. 39.1%). High grade tumors were mostly observed (41%) in basal tumors and were lowest in luminal A (19%). A higher stage at presentation (Stage III and IV) was observed in Her2+ tumours (59%), and a higher (22.4%) mortality was detected in basal like/TN tumours. The molecular classification and sub-typing of BC have revealed ethnic and geographic variation. Luminal A subtype is the most common among Omani female breast cancers but it is less common than in Western females. BCL subtype is highest among Omani females compared with Western females. These differences may have diagnostic, therapeutic and prognostic implications. Large scale and multi-centre studies may confirm these findings and can be translated and incorporated to pertinent management strategies. Key Words: Molecular subtypes, breast cancer, Oman, Royal Hospital.


    • 1 January 2014
      • Vol. 1  (15) , 63-7

    The Dilemma of Serum Tumor Marker (STM) Flares.

    by A Venniyoor, Bassim Al Bahrani, B Rajan

    Serum tumor marker (STM) estimation is often used in clinical practice in monitoring response to treatment and as a predictor of treatment failure and relapse. However, there are pitfalls in interpretation, particularly in the immediate post treatment period, when a rise in titre could be observed, the phenomenon being termed as "flare". A literature search was done to examine this phenomenon for some of the commonly used serum tumor markers in malignancies. This phenomenon has been documented with respect to AFP, beta HCG, CEA, AC 15.3, PSA, CA 19.9 and CA 125 with or without other evidence of progression. Based on this review, a practical approach is suggested so that the clinician is not misled into changing a potentially effective treatment regime. A practical approach would be to correlate serum tumor marker values with other clinical and radiological parameters, and not to rely exclusively on serum marker values to guide therapy. serum, tumor markers, flares, STM, pseudoprogression.


  • Open Access

    Be a true listener, rather than a good conversationalist

    by Itrat Mehdi, Bassim Jaffar Al-Bahrani

    Oncology patient care is an ever evolving field both as a science and a clinical art. We evaluate, diagnose, and treat cancer patients daily. We break the bad and the good news to them. We are the hope on which their life and dreams hang on. We, as practitioners, have to assess each patient as an intelligent observer. We have to devise our strategy to break heartbreaking news to them in a tailored and personalized fashion according to the physical, psychological, emotional, and social status of the patient. The process has to be gentle, perceptive, pragmatic, yet truthful. These need to be reasonably good observational, listening, comprehending, and delivering potentials; which are sharpened by experience and skills.